Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 258 publications.

Earnshaw S, McDade C, Dodoo C, Huynh Z, Zhang K, Chang SN. Economic impact of multiplex point-of-care testing for chlamydia trachomatis, neisseria gonorrhoeae, and mycoplasma genitalium: development of a modeling framework. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Pizzi L, Earnshaw S, Blanchette C, Thompson D. Climbing the HEOR career ladder: strategies for success in an era of change. Presentation to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Clay B, Pop-Busui R, Januzzi JL, Neveux P, Zhang K, McDade C, Earnshaw S. Economic evaluation of NT-proBNP testing to facilitate prevention of heart failure in adults with type 2 diabetes. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Earnshaw S, Brogan AJ, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues - virtual. Presented at the 2024 Virtual ISPOR Short Course Program; December 4, 2024. Previously presented at the 2015 ISPOR 20th Annual International Meeting.

Earnshaw S. Budget impact analysis: a 6 step approach. Presented at the UNC School of Pharmacy; October 24, 2024. Chapel Hill, NC.

Earnshaw S. Role of operations research in supporting access to healthcare technologies. Presented at the NC State University; October 24, 2024. Raleigh, NC.

Mauskopf JA, Mullins CD, Earnshaw S, Brodtkorb TH. Budget impact analysis I: a 6-step approach - virtual. Presented at the ISPOR Virtual Short Course Progam; April 10, 2024. Virtual. Previously presented at the ISPOR 18th Annual European Congress.

McElwee N, Willke R, Barrette E, Berger M, Cole A, Cortesi P, Earnshaw S, Garrison L, Gonzalez-Pier E, IJzerman M, Lee V, Hanson J, Mauskopf J, Reed S. Towards a vision for HEOR: opportunities for enhancement and evolution - an ISPOR health science policy council white paper. 2024. Available at: https://www.ispor.org/member-groups/councils-roundtables/health-science-policy-council. Accessed April 5, 2024.

Earnshaw S, Paret K. The role of operations research in access to pharmaceuticals. Presented at the NC State Operations Research Seminar Series; January 22, 2024. Raleigh, NC.

Onukwugha E, Earnshaw S, Pizzi L, Shukla S. Professional competencies for health economics and outcomes research – 2023 update to the ISPOR Competencies Framework. Presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark.

Brodtkorb T-H, Brogan A, Davis A, Earnshaw S. Budget impact analysis II: applications and design issues. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. Previously presented at the 2022 Virtual ISPOR Short Course Program.

Earnshaw S, Brodtkorb T-H, Mullins D. Budget impact analysis I: a 6-step approach. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. Previously presented at the ISPOR 18th Annual European Congress.

Earnshaw S. Budget impact analysis: a 6-step approach. Presented at the UNC School of Pharmacy AMCP P&T Bootcamp event; October 25, 2023. Chapel Hill, NC.

Earnshaw S. Health economics and outcomes research. Presented at NC State Industrial Engineering course; October 25, 2023. Raleigh NC.

Willke R, McElwee N, Cole A, Berger M, Earnshaw S. Towards broader relevance for HEOR: an HSPC visioning project. Presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA.

Zimmer L, McDade C, Beyhaghi H, Purser M, Textoris J, Krause A, Blanc E, Pavlov V, Earnshaw S. Cost-effectiveness of blood-based brain biomarkers for screening adults with mild traumatic brain injury in the French healthcare setting. J Neurotrauma. 2023 Apr;40(7-8):706-19. doi: 10.1089/neu.2022.0270

Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch DA. Erratum for Earnshaw et al., Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Oct 26;10(5):e0303122. doi: 10.1128/spectrum.03031-22

Earnshaw S, Brogan A, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2022 Virtual ISPOR Short Course Program; September 21, 2022. Previously presented at the 2021 Virtual ISPOR Short Course Program.

Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch D. Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Jun 29;10(3):e0042522. doi: 10.1128/spectrum.00425-22

Davis AE, Earnshaw SR, Mullins CD. Budget impact analysis 1: a 6-step approach. Presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. Previously presented at the ISPOR 18th Annual European Congress.

Earnshaw S, Brogan AJ, Brodtkorb T-H, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2021 Virtual ISPOR Short Course Program; December 6, 2021. Previously presented at the ISPOR 20th Annual International Meeting.

Earnshaw S, Carlsen J, McDade C, Le Coent V, Sable B, Dassaud J. Costs and outcomes associated with large volume delayed sampling and pathogen reduction technology processing given an updated reimbursement approach. Presented at the AABB Virtual 2021 Annual Meeting; October 17, 2021.

Earnshaw S, Beyhaghi H, McDade C, Purser M, Marriott R, Daane L, Le Coent V, Yang J, Toback S. Clinical and economic impacts of large volume delayed sampling and pathogen reduction technology platelet processing strategies in the United States. Transfusion. 2021 Oct;61(10):2885-97. doi: 10.1111/trf.16589

Bryan A, Earnshaw SR, McDade C, Ines M, Micallef C, Enoch DA. Economic evaluation of diagnostic-driven versus empirical treatment strategies in high-risk immunocompromised patients with suspected Aspergillus infection. Poster presented at the 2021 Virtual 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); July 9, 2021.

Mauskopf JA, Mullins CD, Earnshaw SR. Budget impact analysis: a 6-step approach. Presented at the Saudi Ministry of Health; April 2021.

Earnshaw SR, Mauskopf JA, Mullins CD, Brodtkorb T-H. Budget impact analysis I: a 6-step approach. Presented at the ISPOR Virtual Short Course Progam; February 3, 2021. Previously presented at the 2015 ISPOR 18th Annual European Congress.

Earnshaw S, McDade C, Marriott R, Daane L, Le Coent V, Yang J. Costs and outcomes associated with large volume delayed sampling and pathogen reduction technology processing. Poster presented at the 2021 31st International Society of Blood Transfusion (ISBT) Virtual Conference; June 2, 2021. [abstract] Vox Sang. 2021; 116(Suppl 1):167.

Mauskopf J, Earnshaw S. Budget-impact analyses. In: Rascati, K, editors. Essentials of pharmacoeconomics: health economics and outcomes research. 3rd ed. Alphen aan den Rijn: The Netherlands. Wolters Kluwer; 2020.

Purser M, Hartley L, Earnshaw S, Bhaila R, Nag A. Economic models used to evaluate the cost-effectiveness of biologic treatments for ulcerative colitis: a systematic literature review. Poster presented at the 2020 Virtual UEG Week Conference; October 11, 2020.

Purser M, Hartley L, Earnshaw S, Bhaila R, Nag A. Systematic literature review to assess the healthcare resource use and costs associated with ulcerative colitis in adults in Europe. Poster presented at the 2020 Virtual UEG Week Conference; October 11, 2020.

Earnshaw SR, Beyhaghi H, McDade C, Ferris Purser M, Marriott R, Daane L, Le Coent V, Yang J, Toback S. Economic evaluation of large volume delayed sampling and pathogen reduction technology strategies for processing platelets. Poster presented at the 2020 Virtual AABB Annual Meeting; October 2020.

Wilson MR, Wasserman MD, Breton MC, Peloquin F, Earnshaw SR, McDade C, Sings HL, Farkouh RA. Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: a retrospective analysis. Infect Dis Ther. 2020 Aug;9(2):341-53. doi: 10.1007/s40121-020-00294-6

Mullins CD, Earnshaw SR, Brodtkorb T-H. Budget impact analysis I - A 6-step approach. Presented at the 2020 ISPOR Virtual Conference; June 18, 2020.

Beyhaghi H, Zimmer L, McDade C, Purser M, Blanc E, Pavlov V, Earnshaw S. The cost-effectiveness of blood-based brain biomarkers for screening adults with mild traumatic brain injury. Poster presented at the 2020 Digital 33rd European Society of Intensive Care Medicine (ESICM) Congress; December 6, 2020. [abstract] Intensive Care Med Exp. 2020; 8(Suppl 2):000107.

Earnshaw SR, Brogan A, Brodtkorb TH. Budget impact analysis II - applications & design issues. Presented at the ISPOR 2019 European Conference; November 3, 2019. Copenhagen, Denmark. Previously presented at the ISPOR 20th Annual International Meeting.

Mullins CD, Earnshaw SR, Brodtkorb TH. Budget impact analysis I: a 6-step approach. Presented at the ISPOR 2019 European Conference; November 3, 2019. Copenhagen, Denmark. Previously presented at the ISPOR 18th Annual European Congress.

Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. Economic evaluations of biological treatments for moderate-to-severe Crohn's Disease: findings from a systematic literature review. Poster presented at the 2019 United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:907.

Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. The economic burden of Crohn's disease in Europe: findings from a systematic literature review. Poster presented at the 2019 27th United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:906.

Hicks K, Earnshaw S. Demonstrating the use of constrained optimization on a real-world problem. Presented at the 2019 ISPOR 24th Annual International Meeting; May 20, 2019. New Orleans, LA.

Mauskopf JA, Mullins D, Earnshaw SR. Budget impact analysis I: a 6-step approach. Presented at the 2019 ISPOR 24th Annual International Meeting; May 19, 2019. New Orleans, LA. Previously presented at the ISPOR 18th Annual European Congress.

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2019 ISPOR 24th Annual International Meeting; May 19, 2019. New Orleans, LA. Previously presented at the ISPOR 20th Annual International Meeting.

Wilson M, Wasserman M, Breton MC, Peloquin F, McDade C, Earnshaw S, Farkouh R. Estimating the clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Quebec. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Ottawa, Canada.

Wasserman M, Wilson M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Previously presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases.

Earnshaw SR, Brogan AJ, Davis AE. Budget impact analysis II: applications & design issues. Presented at the 2018 ISPOR 21st Annual European Congress; November 11, 2018. Barcelona, Spain. Previously presented at the ISPOR 20th Annual International Meeting.

Mullins CD, Earnshaw SR, Brogan AJ. Budget impact analysis I: a 6-step approach. Presented at the 2018 ISPOR 21st Annual European Congress; November 11, 2018. Barcelona, Spain. Previously presented at the ISPOR 18th Annual European Congress.

Earnshaw SR. Are we ready to use constrained optimization in health outcomes research? - Editorial. Value Health. 2018 Sep;21(9):1029-30. doi: 10.1016/j.jval.2018.07.004

Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018 Sep;7(3):353-71. doi: 10.1007/s40121-018-0206-1

Earnshaw S. The next level in beta-glucan research: new findings for cholesterol-lowering, gut health and more. Presented at the American Society for Nutrition Conference 2018; June 11, 2018. Boston, MA.

Graham J, Earnshaw S, Burslem K, Lim J. Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a U.S. health plan. J Manag Care Spec Pharm. 2018 Jun;24(6):544-53. doi: 10.18553/jmcp.2018.24.6.544

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II – applications and design issues. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 20, 2018. Baltimore, MD. Previously presented at the ISPOR 20th Annual International Meeting.